The development of a successful HIV vaccine will require induction of neutralizing antibodies that can protect from infection by a broad range of HIV isolates. Although antibody responses can be generated as a result of vaccination or infection, these antibodies often recognize only immunodominant, highly variable epitopes that do not confer neutralizing protection. Broadly neutralizing antibodies (BNA) that are capable of neutralizing HIV across clades have been isolated from HIV patients that sustain high CD4 numbers, and low viral titers, over many years. Several of the BNA isolated from this long-term non-progressor (LTNP) population are also reactive to self-antigens, suggesting a relationship with autoreactive B cell development. The B cell source of HIV BNA is unclear. We propose to identify the cellular source of HIV BNA by precisely identifying specific subsets of human B cells using multicolor flow cytometry and to interrogate them with high-throughput technology capable of detecting presumably rare BNA-producing B cells. We will also determine if autoreactive B cells are enriched for HIV BNA. B cells will be isolated from healthy patients and those with HIV and evaluated for the ability to produce HIV BNA. Molecular mimics will be generated against antibodies that recognize the CD4bs of gp120 and any newly identified BNA, that will serve as probes to examine the BNA development and maintenance in HIV patients. The results will be important to define the B cell subsets to be targeted and the type of antigen and adjuvant strategy to stimulate these subsets to become long-lived plasma cells able to sustain BNA production. The development of an effective vaccine to prevent HIV infection will require a better understanding of how to generate antibodies that will neutralize the virus. We propose to precisely identify the B cells that produce protective HIV neutralizing antibodies in order to determine how they arise, are maintained, and how vaccines can be modeled to induce them.

Public Health Relevance

The development of an effective vaccine to prevent HIV infection will require a better understanding of how to generate antibodies that will neutralize the virus. We propose to precisely identify the B cells that produce protective HIV neutralizing antibodies in order to determine how they arise, are maintained, and how vaccines can be modeled to induce them.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI084808-02
Application #
7929534
Study Section
Special Emphasis Panel (ZAI1-SV-A (M2))
Program Officer
Ferguson, Stacy E
Project Start
2009-09-15
Project End
2014-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
2
Fiscal Year
2010
Total Cost
$530,142
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Portugal, Silvia; Tipton, Christopher M; Sohn, Haewon et al. (2015) Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife 4:
Kobie, James J; Zheng, Bo; Piepenbrink, Michael S et al. (2015) Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies. Monoclon Antib Immunodiagn Immunother 34:65-72
Wilmore, Joel R; Asito, Amolo S; Wei, Chungwen et al. (2015) AID expression in peripheral blood of children living in a malaria holoendemic region is associated with changes in B cell subsets and Epstein-Barr virus. Int J Cancer 136:1371-80
Kobie, James J; Treanor, John J; Ritchlin, Christopher T (2014) Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody. Immunol Invest 43:606-15
Alcéna, Danielle C; Kobie, James J; Kaminski, Denise A et al. (2013) 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles. PLoS One 8:e85098
Sullivan, Mark A; Brooks, Lauren R; Weidenborner, Philip et al. (2013) Anti-idiotypic monobodies derived from a fibronectin scaffold. Biochemistry 52:1802-13
Jenks, Scott A; Palmer, Elise M; Marin, Elides Y et al. (2013) 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. Arthritis Rheum 65:3165-75
Richardson, Christopher; Chida, Asiya Seema; Adlowitz, Diana et al. (2013) Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J Immunol 191:4926-39
Sullivan, Mark A; Wentworth, Tim; Kobie, James J et al. (2012) Anti-idiotypic monobodies for immune response profiling. Methods 58:62-8
Kobie, James J; Alcena, Danielle C; Zheng, Bo et al. (2012) 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. PLoS One 7:e35356

Showing the most recent 10 out of 13 publications